| scholarly article | Q13442814 |
| P50 | author | Omer F Kuzu | Q86518955 |
| Gregory R Kardos | Q87832569 | ||
| Raghavendra Gowda | Q88023903 | ||
| Mohammad A Noory | Q88875797 | ||
| Joseph J Drabick | Q88875800 | ||
| SubbaRao V Madhunapantula | Q41550165 | ||
| Gavin P. Robertson | Q55873679 | ||
| Arati Sharma | Q63934950 | ||
| P2093 | author name string | Gavin P Robertson | |
| Omer F Kuzu | |||
| Joseph J Drabick | |||
| Arati Sharma | |||
| Mohammad A Noory | |||
| Gregory Kardos | |||
| P2860 | cites work | Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage | Q24537734 |
| Regulation of the human WEE1Hu CDK tyrosine 15-kinase during the cell cycle | Q24568298 | ||
| Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| TopHat: discovering splice junctions with RNA-Seq | Q24655505 | ||
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells | Q24675189 | ||
| First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 | ||
| Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. | Q27851698 | ||
| Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma | Q27852994 | ||
| Inhibition of Mutated, Activated BRAF in Metastatic Melanoma | Q27860458 | ||
| Cancer statistics, 2015 | Q27860576 | ||
| Achievements and challenges of molecular targeted therapy in melanoma | Q28083501 | ||
| The emerging roles of forkhead box (Fox) proteins in cancer | Q28253741 | ||
| FOXM1, a typical proliferation-associated transcription factor | Q28257808 | ||
| Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas | Q28487835 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| The phosphatidylinositol 3-Kinase AKT pathway in human cancer | Q29547860 | ||
| Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 | ||
| Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K | Q29614757 | ||
| Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 | ||
| PI 3-kinase-dependent phosphorylation of Plk1-Ser99 promotes association with 14-3-3γ and is required for metaphase-anaphase transition | Q30540402 | ||
| Trametinib for patients with advanced melanoma | Q95424350 | ||
| Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma | Q33569998 | ||
| Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2. | Q33647680 | ||
| Akt activation emulates Chk1 inhibition and Bcl2 overexpression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci | Q34025378 | ||
| Akt: a double-edged sword in cell proliferation and genome stability | Q34223641 | ||
| DNA damage-induced apoptosis | Q34312499 | ||
| Deregulated Akt3 activity promotes development of malignant melanoma | Q34355872 | ||
| Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport. | Q34413011 | ||
| PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression | Q34761941 | ||
| Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gamma-irradiation | Q34946238 | ||
| New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? | Q35057304 | ||
| BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model | Q35090029 | ||
| Targeting multiple key signaling pathways in melanoma using leelamine. | Q35136450 | ||
| Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma. | Q35225907 | ||
| BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance | Q35607456 | ||
| Akt inhibitors in clinical development for the treatment of cancer | Q35628576 | ||
| The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors. | Q36020990 | ||
| Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma | Q36750123 | ||
| A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis | Q37085216 | ||
| Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases | Q37421620 | ||
| The "SWOT" of BRAF inhibition in melanoma: RAF inhibitors, MEK inhibitors or both? | Q37945533 | ||
| Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease | Q38256335 | ||
| Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma. | Q38724921 | ||
| Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth. | Q38738291 | ||
| Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. | Q39268913 | ||
| The tricyclic antidepressant imipramine induces autophagic cell death in U-87MG glioma cells | Q39479966 | ||
| Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma | Q39687000 | ||
| Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. | Q39899988 | ||
| PRAS40 deregulates apoptosis in malignant melanoma | Q40144591 | ||
| Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors | Q40444060 | ||
| Inhibition of Chk1 by activated PKB/Akt. | Q40563144 | ||
| Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. | Q41859138 | ||
| In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma | Q42758535 | ||
| Akt is more than just a Bad kinase | Q59068251 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P433 | issue | 1 | |
| P304 | page(s) | 53-62 | |
| P577 | publication date | 2017-11-30 | |
| P1433 | published in | Cancer Biology and Therapy | Q2544651 |
| P1476 | title | Identification of WEE1 as a target to make AKT inhibition more effective in melanoma | |
| P478 | volume | 19 |
| Q90044630 | Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status |
| Q57044361 | Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy |
| Q47292160 | Moving synergistically acting drug combinations to the clinic by comparing sequential versus simultaneous drug administrations |
| Q49724275 | Repression of Akt3 gene transcription by the tumor suppressor RIZ1. |
Search more.